RALA and chronic myelogenous leukemia, BCR-ABL1 positive: To assess whether RalA expression promotes imatinib resistance in vivo, BMCs from RalARosa26-Tg/+ and RalA+/+ mice were transduced to construct the mouse model of BCR-ABL-driven CML and then exposed to imatinib (100 mg/kg/day, gavage) (Figure 5E).